Jerry S.H. Lee, Ph.D.
Dr. Lee serves as a Health Sciences Director within the National Cancer Institute’s (NCI) Office of the Director where his chief responsibility is to help direct the NCI’s Center for Strategic Scientific Initiatives (CSSI). In this role, he provides leadership and input in planning, developing, and implementing rapid strategic scientific and technology initiatives that keep the Institute ahead of the scientific curve of potential new exciting areas and discoveries. This may involve direct development and application of advanced technologies, creation of new trans-disciplinary teams, and/or use of available federal funding mechanisms to forge novel partnerships that emphasize innovation and convergence of scientific disciplines.
Specifically, Dr. Lee oversees scientific, programmatic, and operational aspects of CSSI’s portfolio (~$161.3 million in FY14) and provides leadership in planning, developing, and implementing various CSSI programs. Since its inception in 2003, the Center has supported ~1,700 trans-disciplinary projects (~$1,088 million FY05 – FY14) through programs such as Innovation Molecular Analysis Technologies (IMAT), NCI Alliance for Nanotechnology in Cancer, The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), Physical Sciences-Oncology Centers (PS-OC), Provocative Questions (PQ), and Cancer Target Discovery and Development (CTD2) network. These exploratory initiatives focus on the integration of advanced technologies, trans-disciplinary approaches, infrastructures, and standards, to accelerate the creation of publicly available, broadly accessible, multi-dimensional data, knowledge, and tools to empower the entire cancer research continuum for patient benefit.
Prior to joining the NCI, Dr. Lee’s research experience involved elucidating mechanisms of age-related diseases by combining cell biology, molecular biology, and engineering approaches to understand various cellular reactions to external stimuli. He has co-authored over twenty papers, five book chapters, and one book on the role of Rho GTPase-mediated nuclear and cellular mechanical responses to fluid flow and 3D culture and demonstrated their potential impact in diseases such as progeria and cancer. Dr. Lee continues research as an adjunct associate professor at Johns Hopkins University where he also earned his bachelor's degree in biomedical engineering and Ph.D. in chemical and biomolecular engineering. He also holds an appointment at the Washington D.C. Veterans Affairs Medical Center and collaborates with clinicians on next generation patient-centered outcomes research. He is an active member of the American Association for Cancer Research, Biomedical Engineering Society, Biophysical Society, American Society of Mechanical Engineers, American Society for Cell Biology, and Tau Beta Pi. Dr. Lee also serves as member of the Innovation Policy Forum of the National Academies Board on Science, Technology, and Economic Policy; Foundation for the NIH’s Biomarkers’ Consortium Cancer Steering Committee; Health and Environmental Sciences Institute’s Board of Trustees; and the editorial board of Convergence Science Physical Oncology journal.
Jerry S.H. Lee, Ph.D.
Center for Strategic Scientific Initiatives
Office of the Director
National Cancer Institute, National Institutes of Health
Department of Health and Human Services